Titan Pharmaceuticals, Inc. (TTNP) Rating Increased to Hold at TheStreet

Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP) was upgraded by equities researchers at TheStreet from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

Titan Pharmaceuticals (OTCMKTS:TTNP) opened at 5.96 on Thursday. Titan Pharmaceuticals has a one year low of $2.57 and a one year high of $8.74. The stock has a 50 day moving average price of $5.75 and a 200 day moving average price of $5.61. The firm has a market cap of $126.34 million and a PE ratio of 20.14.

Titan Pharmaceuticals (OTCMKTS:TTNP) last announced its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.02. The company earned $15 million during the quarter, compared to analyst estimates of $15 million. Equities research analysts expect that Titan Pharmaceuticals will post $0.25 EPS for the current year.

In other Titan Pharmaceuticals news, Director Joseph A. Akers bought 13,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 19th. The shares were purchased at an average price of $4.85 per share, with a total value of $63,050.00. Following the completion of the acquisition, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $38,800. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sunil Bhonsle bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 18th. The stock was acquired at an average cost of $4.96 per share, for a total transaction of $49,600.00. Following the acquisition, the chief executive officer now directly owns 135,578 shares of the company’s stock, valued at $672,466.88. The disclosure for this purchase can be found here.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura.

Receive News & Ratings for Titan Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.